贝利尤单抗联合标准方案治疗活动性狼疮性肾炎的临床价值研究  

Study the clinical value of Belimumab combined with standard of care in the treatment of active lupus nephritis

作　　者：刘晓莉 LIU Xiao-li(Department of Nephrology,Shanting District People's Hospital,Zaozhuang,277500,China)

机构地区：[1]枣庄市山亭区人民医院肾内科,277500

出　　处：《中国现代药物应用》2025年第2期94-97,共4页Chinese Journal of Modern Drug Application

摘　　要：目的 分析活动性狼疮性肾炎(LN)患者接受贝利尤单抗联合标准方案治疗(SoC)的临床价值。方法 选取活动性LN患者62例,遵循随机抽签法将其分为比对组、联合组,每组31例。比对组患者给予SoC治疗,联合组患者在比对组治疗基础上增加贝利尤单抗治疗。比较两组患者不良反应发生情况以及治疗6、32周的相关指标参数[24 h尿蛋白定量、糖皮质激素用量、白蛋白(ALB)、血肌酐(SCr)、补体C3(C3)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)、B细胞计数、B淋巴细胞占比]。结果 联合组患者不良反应发生率3.23%显著低于比对组的25.81%,差异有统计意义(P<0.05)。联合组患者治疗6、32周的24 h尿蛋白定量分别为(407.16±310.22)、(164.43±116.32)mg/24 h,糖皮质激素用量分别为(28.43±11.16)、(7.63±3.16)mg/d,ALB分别为(34.76±4.21)、(41.65±3.19)g/L,SCr分别为(77.16±12.14)、(61.34±17.13)μmol/L,C3分别为(0.81±0.22)、(0.93±0.12)g/L,IL-6分别为(9.56±2.23)、(4.61±2.83)pg/ml,IL-10分别为(16.63±7.14)、(3.27±1.21)pg/ml,B细胞计数分别为(196.61±88.93)、(56.37±20.17)×10^(9)/L,B淋巴细胞占比分别为(14.71±4.32)%、(3.93±2.34)%;比对组患者治疗6、32周的24 h尿蛋白定量分别为(587.23±372.19)、(396.61±312.18)mg/24 h,糖皮质激素用量分别为(36.73±13.28)、(13.71±4.23)mg/d,ALB分别为(31.62±4.73)、(38.62±3.31)g/L,SCr分别为(86.26±13.71)、(70.63±17.22)μmol/L,C3分别为(0.62±0.21)、(0.86±0.13)g/L,IL-6分别为(11.32±2.71)、(6.67±2.12)pg/ml,IL-10分别为(21.24±7.22)、(8.24±1.16)pg/ml,B细胞计数分别为(243.21±87.62)、(96.34±20.83)×10^(9)/L,B淋巴细胞占比分别为(17.24±4.07)%、(8.66±2.14)%。联合组患者治疗6、32周的24 h尿蛋白定量、糖皮质激素用量、SCr、IL-6、IL-10、B细胞计数、B淋巴细胞占比均低于比对组,ALB、C3均高于比对组,差异有统计意义(P<0.05)。结论 在活动性LN的治疗中,使用贝利尤单抗联合SoC治疗方式Objective To analyze the clinical value of Belimumab combined with standard of care (SoC)in the treatment of active lupus nephritis (LN).Methods 62 patients with active LN were included,and were divided into comparison group and combination group by random lottery method,with 31 cases in each group.The comparison group was given SoC treatment,while the combination group was treated with Belimumab based on the comparison group.Patients in both groups were compared in terms of adverse reactions,relevant indicators and parameters[24 h urinary protein quantification,glucocorticoid dosage,albumin (ALB),serum creatinine(SCr),complement C3(C3),interleukin-6 (IL-6),interleukin-10 (IL-10),B cell count,B lymphocyte percentage]at 6 weeks and 32 weeks of treatment.Results The incidence of adverse reactions of 3.23%in the combination group was significantly lower than 25.81%in the comparison group,and the difference was statistically significant(P<0.05).In the combination group,the 24 h urinary protein quantification at 6 and 32 weeks of treatment were(407.16±310.22) and (164.43±116.32) mg/24 h,the glucocorticoid dosage were (28.43±11.16) and (7.63±3.16) mg/d,ALB were (34.76±4.21) and (41.65±3.19) g/L,SCr were (77.16±12.14) and (61.34±17.13)μmol/L,C3 were (0.81±0.22) and (0.93±0.12) g/L,IL-6 were (9.56±2.23) and (4.61±2.83) pg/ml,IL-10 were(16.63±7.14) and (3.27±1.21) pg/ml,B cell count were (196.61±88.93)×10^(9)/L and (56.37±20.17)×10^(9)/L,and the B lymphocyte percentage were (14.71±4.32)%and (3.93±2.34)%.In the comparison group,the24 h urinary protein quantification at 6 and 32 weeks of treatment were (587.23±372.19) and (396.61±312.18) mg/24 h,the glucocorticoid dosage were (36.73±13.28) and (13.71±4.23) mg/d,ALB were (31.62±4.73and (38.62±3.31) g/L,SCr were (86.26±13.71) and (70.63±17.22)μmol/L,C3 were (0.62±0.21) and(0.86±0.13) g/L,IL-6 were (11.32±2.71) and (6.67±2.12) pg/ml,IL-10 were (21.24±7.22) and (8.24±1.16) pg/ml,B cell count were (243.21±87.62)×10^(9)/L and (96.34±20.83)×

关 键 词：贝利尤单抗 标准方案治疗 活动性狼疮性肾炎 不良反应 

分 类 号：R593.242[医药卫生—内科学]